Workflow
Long-acting anti-NGF mAb therapy
icon
Search documents
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Businesswire· 2025-09-12 16:09
Core Viewpoint - Zoetis is seeking approval for Portela, which would be the first long-acting anti-NGF monoclonal antibody therapy for cats, aimed at providing three months of osteoarthritis pain relief [1] Company Summary - Portela is designed specifically for cats, indicating a targeted approach in the veterinary pharmaceutical market [1] - The therapy's long-acting nature suggests a potential shift in how osteoarthritis pain is managed in felines, which could enhance the quality of life for affected animals [1] Industry Summary - The introduction of long-acting therapies in veterinary medicine reflects a growing trend towards innovative treatments for chronic conditions in pets [1] - This development may position Zoetis favorably within the animal health industry, particularly in the segment focused on pain management solutions [1]